PDF(Pubmed)
Abstract：
BACKGROUND: Increasing evidence suggested that immune abnormalities involved in the pathophysiology of schizophrenia. However, the relationship between immunity and clinical features has not been clarified. The aim of this study was to measure the plasma levels of tumor necrosis factor alpha (TNF-α) and soluble TNF-α receptor 1 (sTNF-α R1) and to investigate their association with agitation in first episode patients with schizophrenia (FEPS).
METHODS: The plasma TNF-α and sTNF-α R1 levels were measured using sandwich enzyme-linked immunosorbent assay (ELISA) in the FEPS with (n = 36) and without agitation (n = 49) symptoms, and healthy controls (HCs, n = 54). The psychopathology was assessed by the Positive and Negative Syndrome Scale (PANSS), and the agitation symptoms were evaluated by the PANSS excitatory component (PANSS-EC).
RESULTS: The plasma TNF-α levels in patients with and without agitation symptoms were significantly higher than those in HCs. The patients with agitation had significantly higher plasma TNF-α levels compared to the patients without agitation. There were no significant differences in the sTNF-α R1 levels among the three groups. Furthermore, the plasma TNF-α levels were positively correlated with the PANSS total score, Positive and General psychopathological subscores, and PANSS-EC score in the FEPS, but the relationships were not found for the plasma sTNF-α R1 levels.
CONCLUSIONS: These results suggested that TNF-α might play an important role in the onset and development of agitation symptoms of schizophrenia.
METHODS: The plasma TNF-α and sTNF-α R1 levels were measured using sandwich enzyme-linked immunosorbent assay (ELISA) in the FEPS with (n = 36) and without agitation (n = 49) symptoms, and healthy controls (HCs, n = 54). The psychopathology was assessed by the Positive and Negative Syndrome Scale (PANSS), and the agitation symptoms were evaluated by the PANSS excitatory component (PANSS-EC).
RESULTS: The plasma TNF-α levels in patients with and without agitation symptoms were significantly higher than those in HCs. The patients with agitation had significantly higher plasma TNF-α levels compared to the patients without agitation. There were no significant differences in the sTNF-α R1 levels among the three groups. Furthermore, the plasma TNF-α levels were positively correlated with the PANSS total score, Positive and General psychopathological subscores, and PANSS-EC score in the FEPS, but the relationships were not found for the plasma sTNF-α R1 levels.
CONCLUSIONS: These results suggested that TNF-α might play an important role in the onset and development of agitation symptoms of schizophrenia.
摘要：
背景：越来越多的证据表明免疫异常与精神分裂症的病理生理有关。然而,免疫与临床特征之间的关系尚未阐明。这项研究的目的是测量血浆中肿瘤坏死因子α（TNF-α）和可溶性TNF-α受体1（sTNF-αR1）的水平，并研究它们与首发精神分裂症患者躁动的关系（FEPS）。
方法：在有（n=36）和无激动（n=49）症状的FEPS中，使用夹心酶联免疫吸附测定（ELISA）测量血浆TNF-α和sTNF-αR1水平，和健康对照(HC，n=54）。精神病理学通过阳性和阴性综合征量表(PANSS)进行评估，通过PANSS兴奋性成分（PANSS-EC）评估躁动症状。
结果：有和没有躁动症状的患者的血浆TNF-α水平明显高于HCs。与没有躁动的患者相比，有躁动的患者的血浆TNF-α水平明显更高。三组间sTNF-αR1水平差异无统计学意义。此外，血浆TNF-α水平与PANSS总分呈正相关,阳性和一般精神病理学子评分，和PANSS-EC得分，但未发现血浆sTNF-αR1水平的关系。
结论：这些结果表明，TNF-α可能在精神分裂症躁动症状的发生和发展中起重要作用。
方法：在有（n=36）和无激动（n=49）症状的FEPS中，使用夹心酶联免疫吸附测定（ELISA）测量血浆TNF-α和sTNF-αR1水平，和健康对照(HC，n=54）。精神病理学通过阳性和阴性综合征量表(PANSS)进行评估，通过PANSS兴奋性成分（PANSS-EC）评估躁动症状。
结果：有和没有躁动症状的患者的血浆TNF-α水平明显高于HCs。与没有躁动的患者相比，有躁动的患者的血浆TNF-α水平明显更高。三组间sTNF-αR1水平差异无统计学意义。此外，血浆TNF-α水平与PANSS总分呈正相关,阳性和一般精神病理学子评分，和PANSS-EC得分，但未发现血浆sTNF-αR1水平的关系。
结论：这些结果表明，TNF-α可能在精神分裂症躁动症状的发生和发展中起重要作用。
